A 301

Nogotrienone is an anabolic steroid with fertility and contraceptive activity that has been studied as a therapeutic agent for hereditary angioneurotic edema.

AK301 is a potent and selective inhibitor of tubulin polymerization and an effective sensitizer of cancer cells to apoptotic ligands (EC50 < 200 nM). Colon cancer cells arrested in mitosis with AK301 readily underwent a p53-dependent apoptosis following compound withdrawal and arrest release.

TIK-301 is a chlorinated melatonin derivative and a potent, high-affinity, and orally active melatonin MT1 and MT2 receptors agonist (Kis: 0.081 nM and 0.042 nM, respectively). TIK-301 is also a 5-HT2B/5-HT2C receptor antagonist with antidepressant action. TIK-301 has the potential for sleep disorders and other circadian rhythm disorders treatment.

TT-301 is a cytokine inhibitor and glial cell inhibitor.

LEI-301 is a novel potent inhibitor for the PLAAT family members, reducing the NAE levels, including anandamide, in cells overexpressing PLAAT2 or PLAAT5.

UH 301 is a 5-HT1A receptor antagonist.

LabMol-301, a chemical compound, effectively inhibits NS5 RdRp and NS2B-NS3pro activity with IC50 values of 0.8 μM and 7.4 μM, respectively. Additionally, it exhibits cytoprotective effects, safeguarding against Zika virus (ZIKV)-induced cell death.

LWG-301, an allosteric inhibitor of Glutaminase 1 (GLS1), demonstrates a potent inhibition with an IC50 value of 7 nM. It effectively impedes glutamine metabolism and elevates intracellular ROS levels, thereby inducing apoptosis. Additionally, LWG-301 shows moderate antitumor efficacy in the HCT116 xenograft model.

RU-301 is a novel pan-tam inhibitor

4A7C-301, a Nurr1 agonist, exhibits potent neuroprotective effects in vitro and markedly mitigates neuropathological abnormalities while enhancing motor and olfactory functions in male mouse models with AAV2-mediated α-synuclein overexpression. This compound is applicable in Parkinson's disease research [1].

The compound 4A7C-301-Nurr1 agonist is a specific agonist for the nuclear receptor-related 1 (Nurr1). By binding to the Nurr1 ligand-binding domain with an IC50 value of 48.22 nM, it enhances the transcriptional activity of both Nurr1-LBD and the full-length Nurr1, as demonstrated in reporter assays using SK-N-BE(2)C human neuroblastoma cells, with EC50 values of 6.53 and 50-70 µM, respectively. Additionally, administration of 4A7C-301-Nurr1 agonist at a dosage of 5 mg/kg per day has been shown to mitigate dopaminergic cell death in the striatum and substantia nigra pars compacta and ameliorate motor and olfactory deficits in mouse models of Parkinson's disease, circumventing the induction of dyskinesia-like behaviors. These models were induced either by the neurotoxin MPTP or by overexpression of α-synuclein.

IMB-301 is a small molecular inhibitor via virtual screening according to the hA3G model.

SAIT-301 is a humanized antibody expressed in CHO cells, targeting HGFR/c-Met. It consists of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of SAIT-301, refer to HumanIgG1kappa, Isotype Control.

Anti-CLDN6 Antibody (IM-301) is a CHO-expressed human antibody targeting CLDN6. It features an IgG1 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 150 kDa.

NI-301 is a human monoclonal antibody (mAb) that targets Transthyretin/TTR. It is applicable for research in cardiomyopathy and familial amyloid polyneuropathy.

BLX-301 is a humanized monoclonal antibody against CD20, exhibiting antitumor activity. It is applicable in studies related to diseases such as non-Hodgkin's lymphoma and rheumatoid arthritis.

JKC 301, a selective Endothelin A receptor antagonist, attenuates the pressor effects of nicotine in rats and can be used to study cardiovascular disease caused by smoking [1] [2].

KMG-301AM, the acetoxy methyl esterified form of KMG-301, facilitates the acquisition of time-course and pseudo-colored images depicting the changes in mitochondrial fluorescence when stained with KMG-301.

TH301 acts as a stabilizer for cryptochrome circadian regulator 2 (CRY2). It demonstrates selectivity by stabilizing CRY2 over CRY1 in a degradation assay conducted with HEK293 cells expressing CRY reporters at concentrations ranging from 0.1 to 10 µM. In wild-type mouse fibroblasts, TH301 extends the circadian period, but this effect is absent in Cry2-/- fibroblasts. Additionally, it boosts rosiglitazone-dependent induction of brown adipose tissue-specific genes such as Ucp1, Cidea, and Kcnk3 in primary mouse stromal vascular fractions.

UBP301 is a kainate receptor antagonist.

TAS-301, an inhibitor of smooth muscle cell migration and proliferation, inhibits intimal thickening after balloon injury to rat carotid arteries.

NQ301, an antithrombotic agent, inhibits collagen-challenged rabbit platelet aggregation (IC50: 10 mg/mL).

ALM301 is a highly specific, orally active AKT inhibitor that acts on AKT1 (IC50: 0.13 μM), AKT2 (IC50: 0.09 μM) and AKT3 (IC50: 2.75 μM). ALM301 inhibits AKT phosphorylation in vitro and has a regulatory effect on downstream signalling. ALM301 exhibits inhibitory effects on cancer cell proliferation and tumor growth.

Anti-Mouse CD47/IAP Antibody (MIAP301) is a monoclonal antibody inhibitor targeting mouse CD47/IAP. It enhances macrophage phagocytosis and immune cell infiltration, restores myeloid cell phagocytic function, and alleviates B-cell suppression. It can be used in research on cancer, inflammation, and infectious diseases.